HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Lowers Price Target to $4

Benzinga · 4d ago
HC Wainwright & Co. analyst Matthew Caufield maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and lowers the price target from $6 to $4.